Good
Mostly Aligned
Patient Risk:
Moderate
Summary
Most claims match labeled indication, diagnostic use, single oral dosing, oral solution administration, and blood sampling timing/mechanism. Several details are either incomplete or not fully supported (e.g., specific adverse reactions only listed generally, and some interpretive/specific-context wording).
Category Scores
Accurate Statements
Macrilen is the brand name for macimorelin.
Label identifies MACRILEN and active ingredient macimorelin (macimorelin acetate).
Macrilen is a prescription medicine.
Prescription status is consistent with FDA labeling context provided (label provided for MACRILEN).
Macrilen is used as a diagnostic test to determine whether the body is producing enough growth hormone (GH).
Indications: diagnosis of adult growth hormone deficiency (AGHD).
Macrilen works by stimulating the pituitary gland to release growth hormone after a dose is taken.
Mechanism of action: stimulates GH release by activating growth hormone secretagogue receptors present in the pituitary and hypothalamus; GH stimulation observed 30–90 minutes.
After taking Macrilen, growth hormone levels are measured with blood tests.
Directions for administration: venous blood samples drawn for GH determination at 30, 45, 60, and 90 minutes.
The test is used to assess adult growth hormone deficiency and related conditions.
Indications: diagnosis of adult growth hormone deficiency (AGHD).
Macrilen is administered as a single oral dose.
Recommended dose: single oral dose of 0.5 mg/kg; Directions specify administration and sampling after administration.
After the single oral dose of Macrilen, blood samples are collected over a set period to measure growth hormone levels in response to the medicine.
Venous blood samples at 30, 45, 60, and 90 minutes after administration.
Clinicians interpret Macrilen test GH results to judge whether there is growth hormone deficiency.
Interpretation of test results: maximally stimulated serum GH level <2.8 ng/mL confirms presence of adult GH deficiency.
Macrilen is used for evaluating possible growth hormone deficiency in adults.
Indications: diagnosis of adult growth hormone deficiency (AGHD).
Macrilen is a diagnostic tool rather than a treatment for growth hormone deficiency.
Indications and interpretation section describe diagnostic use for confirming AGHD; label does not present MACRILEN as GH replacement therapy.
Macrilen is taken by mouth (oral administration).
Recommended dose is a single oral dose; dosage form is oral solution.
Macrilen relies on a measured GH response after dosing.
Interpretation uses maximally stimulated serum GH level after MACRILEN administration; GH stimulation described.
Macrilen is not the same as growth hormone replacement.
Label distinguishes diagnostic test from growth hormone products (e.g., growth hormone therapy discontinuation and 'growth hormone products' in drug interactions).
Macrilen is used to diagnose growth hormone deficiency by measuring the body’s GH response.
Indications; Interpretation of test results; Clinical pharmacology and timing of GH measurement.
Growth hormone replacement uses different medications.
Drug interactions section references 'growth hormone products' and recommends discontinuation prior to diagnostic testing.
Growth hormone replacement is prescribed only if deficiency is confirmed.
Supported indirectly by label requirement for diagnostic confirmation threshold (<2.8 ng/mL) to confirm adult GH deficiency.
Unsupported Statements
Possible side effects reported with Macrilen include headache.
The provided label excerpts under Adverse Reactions do not list specific adverse events such as headache.
Possible side effects reported with Macrilen include nausea.
The provided label excerpts under Adverse Reactions do not list specific adverse events such as nausea.
Possible side effects reported with Macrilen include abdominal discomfort.
The provided label excerpts under Adverse Reactions do not list specific adverse events such as abdominal discomfort.
Possible side effects reported with Macrilen include changes in appetite.
The provided label excerpts under Adverse Reactions do not list specific adverse events such as changes in appetite.
The test is used to assess adult growth hormone deficiency and related conditions.
Label provided states diagnosis of adult growth hormone deficiency; 'related conditions' is not specified in the supplied label text.
Growth hormone replacement is prescribed only if deficiency is confirmed.
Label provided establishes diagnostic confirmation threshold for AGHD; it does not state prescribing conditions for growth hormone replacement therapy.
Contradictions
Important Omissions
Dose amount and fasting requirement: 0.5 mg/kg single oral dose and fasted for at least 8 hours prior to administration.
Importance:
Moderate
Specific blood draw timepoints (30, 45, 60, 90 minutes) rather than a generic 'set period'.
Importance:
Moderate
Diagnostic cutoff: maximally stimulated serum GH <2.8 ng/mL confirms AGHD (including reference to 30/45/60/90-minute timepoints).
Importance:
High
Label limitations/precautions that affect diagnostic performance (e.g., BMI > 40 kg/m2 limitation; false positive with strong CYP3A4 inducers; false negative early hypothalamic disease; QT prolongation caution with QT-prolonging drugs).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Main safety-impacting label elements (diagnostic cutoff, fasting, and key precautions affecting diagnostic accuracy such as drug interactions and QT prolongation) are omitted or not fully specified in the claims. However, no direct contradictions to the supplied label were made.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Several important labeled specifics are missing (fasting requirement, diagnostic cutoff <2.8 ng/mL, and key diagnostic-performance precautions), and adverse reaction examples (headache/nausea/etc.) are not supported by the provided label excerpts.
Suggested Improvement
Include the labeled diagnostic details (fast at least 8 hours; recommended dose 0.5 mg/kg; draw GH at 30/45/60/90 minutes; interpret using maximally stimulated GH <2.8 ng/mL). Remove or qualify unsourced adverse event claims unless adverse reactions are explicitly listed in the provided label text. Optionally mention key precautions that affect test accuracy/performance (strong CYP3A4 inducers, QT-prolonging drugs, and potential false negatives early in hypothalamic disease).